We are live on ! Find out more
ALLO icon

Allogene Therapeutics

172 hedge funds and large institutions have $201M invested in Allogene Therapeutics in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 61 increasing their positions, 37 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more call options, than puts

Call options by funds: $120K | Put options by funds: $48K

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

65% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 37

8% more funds holding

Funds holding: 160 → 172 (+12)

10.89% less ownership

Funds ownership: 83.95% → 73.06% (-11%)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

48% less capital inflows, than outflows

Capital inflows: $26.5M | Capital outflows: $51M

Holders
172
Holders Change
+12
Holders Change %
+7.5%
% of All Funds
2.24%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
30
Increased
61
Reduced
37
Closed
16
Calls
$120K
Puts
$48K
Net Calls
+$72K
Net Calls Change
+$11K

ALLO Hedge Fund Activity: Q3 2025 in Review

172 of the 7,664 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2025, worth a combined $201M — down 3.3% from $208M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ALLO positions and 16 closed out — a net gain of 14 holders — while 61 added to existing stakes and 37 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $4.43M. The largest seller was Capital World Investors, exiting entirely with an estimated $12.6M sold.

  • 172 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2025, up from 160 in Q2 2025.
  • Funds reported $201M of Allogene Therapeutics stock for Q3 2025, down 3.3% quarter-over-quarter.
  • 30 funds opened new Allogene Therapeutics positions in Q3 2025 and 16 closed out, a net change of +14 holders.
  • The largest Allogene Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $4.43M added.
  • The largest Allogene Therapeutics seller in Q3 2025 was Capital World Investors, an estimated $12.6M sold.

Based on aggregated 13F filings for Q3 2025.